Skip to content
lifestyle.lincolnlabs.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren’s Disease
September 23, 2026
Artiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
September 17, 2026
Artiva Biotherapeutics: AlloNK Phase 3 RA Trial & 2026 Data Updates
September 8, 2026
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September
September 2, 2026
Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
August 6, 2026
Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 17, 2026
Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
June 23, 2026
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases
May 19, 2026
Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development
May 19, 2026
Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
May 8, 2026
1
2
Next Page
→